Citigroup Inc. restated their outperform rating on shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) in a research note published on Thursday. Citigroup Inc. currently has a $15.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $8.00.
A number of other equities analysts also recently issued reports on CBAY. HC Wainwright increased their price objective on shares of CymaBay Therapeutics from $7.00 to $12.00 and gave the company a buy rating in a research note on Monday. Piper Jaffray Companies set a $7.00 price objective on shares of CymaBay Therapeutics and gave the company a buy rating in a research note on Monday. Ifs Securities reiterated a strong-buy rating on shares of CymaBay Therapeutics in a research note on Monday. ValuEngine upgraded shares of CymaBay Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. Finally, Oppenheimer Holdings Inc. began coverage on shares of CymaBay Therapeutics in a research note on Friday, June 23rd. They set an outperform rating and a $8.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $11.04.
Shares of CymaBay Therapeutics (CBAY) traded up 6.16% during mid-day trading on Thursday, reaching $7.75. 2,636,436 shares of the company’s stock traded hands. The firm’s market capitalization is $222.83 million. The stock has a 50-day moving average price of $5.37 and a 200 day moving average price of $3.80. CymaBay Therapeutics has a 12-month low of $1.15 and a 12-month high of $7.94.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.07. The business had revenue of $4.79 million for the quarter. Analysts anticipate that CymaBay Therapeutics will post ($0.83) EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. LVM Capital Management Ltd. MI boosted its stake in CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 10,000 shares during the last quarter. Boxer Capital LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth approximately $3,342,000. Renaissance Technologies LLC boosted its stake in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 114,549 shares during the last quarter. ClariVest Asset Management LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth approximately $105,000. Finally, TFS Capital LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth approximately $169,000. 36.87% of the stock is owned by institutional investors.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
